title: Antiplatelet therapy in atherothrombotic cardiovascular diseases for primary and secondary prevention: a focus on old and new antiplatelet agents.
abstract: Aspirin has long been the mainstay of primary and secondary prevention against myocardial infarction and ischemic cerebrovascular events. However, the incremental value of aspirin for primary prevention has recently been subject to debate given data from recent large clinical trials, as the net clinical benefit is small. In secondary prevention, aspirin is still strongly recommended. Efforts in obtaining more efficient antiplatelet agents and to reduce cardiovascular morbidity and mortality have led to the development of new adenosine diphosphate (ADP) receptor antagonists, which are superior to clopidogrel. New generation antiplatelet drugs i.e. prasugrel and ticagrelor aim to reduce atherothrombotic events, mortality and stent thrombosis, as well as overcome low- or non-response to clopidogrel. Further agents with antiplatelet properties are being investigated at present. This overview aims to give insights into the rapidly changing field of antiplatelet strategies in cardiovascular diseases.
authors.affiliation: Centre for Cardiovascular Sciences, City Hospital, B18 7QH, Birmingham, England, UK.
authors.forename: Burak
authors.initials: B
authors.lastname: Pamukcu
authors.forename: Kurt
authors.initials: K
authors.lastname: Huber
authors.forename: Gregory Y H
authors.initials: GY
authors.lastname: Lip
mesh_terms: D000991:Antithrombins / Q000494:pharmacology*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D058921:Purinergic P2Y Receptor Antagonists / Q000494:pharmacology*; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D000991:Antithrombins; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists